UroGen Pharma (FRA:UR8) EBIT: €-105.7 Mil (TTM As of Mar. 2026)


FRA:UR8 UroGen Pharma Ltd FRA:UR8
67 GF Score
Price €29.44
GF Value €17.05
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is UroGen Pharma EBIT?

UroGen Pharma FRA:UR8 -3.22% 67 EBIT is €-105.7 Mil as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 67/100 and a GF Value™ of €17.05 (Significantly Overvalued). The stock has 9 warning signs investors should review.

UroGen Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-20.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-105.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. UroGen Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was -103.94%. UroGen Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -232.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. UroGen Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -6.93%.

UroGen Pharma  (FRA:UR8) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

UroGen Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-70.108 * ( 1 - 16.84% )/( (44.65 + 67.531)/ 2 )
=-58.3018128/56.0905
=-103.94 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=171.189 - 23.67 - ( 102.869 - max(0, 39.641 - 158.864+102.869))
=44.65

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=219.442 - 30.574 - ( 121.337 - max(0, 43.799 - 205.406+121.337))
=67.531

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

UroGen Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-83.596/( ( (7.765 + max(16.354, 0)) + (7.401 + max(40.27, 0)) )/ 2 )
=-83.596/( ( 24.119 + 47.671 )/ 2 )
=-83.596/35.895
=-232.89 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.252 + 14.06 + 13.683) - (23.67 + 0 + 15.971)
=16.354

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(47.931 + 18.097 + 18.041) - (30.574 + 0 + 13.225)
=40.27

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

UroGen Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-105.699/1526.225
=-6.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma EBIT Related Terms

UroGen Pharma EBIT Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma EBIT Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.79 -94.01 -76.67 -106.50 -117.91

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.43 -38.84 -26.44 -19.53 -20.90

FRA:UR8 vs OCS, SEPN, AVBP: EBIT Comparison

For the Biotechnology subindustry, UroGen Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's EV-to-EBIT falls into.


FRA:UR8
67GF Score
UroGen Pharma Ltd FRA:UR8
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-105.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-105.7 Mil mean?
UroGen Pharma (FRA:UR8) has a EBIT of €-105.7 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on UroGen Pharma.
Is UroGen Pharma's EBIT too high?
UroGen Pharma's current EBIT is €-105.7 Mil. Overall, UroGen Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's EBIT compare to OCS and SEPN?
UroGen Pharma's EBIT of €-105.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on UroGen Pharma. UroGen Pharma's current EBIT is €-105.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.05, compared to a current price of €29.44 — trading 72.7% above its estimated fair value. The current EBIT is €-105.7 Mil. UroGen Pharma's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current EBIT is €-105.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €29.44 is trading 72.7% above its estimated GF Value™ of €17.05. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • EBIT: €-105.7 Mil
  • GF Value™: €17.05 vs. price of €29.44 (72.7% above fair value)
  • GF Score™: 67/100 with 9 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
67GF Score

Get the complete analysis for FRA:UR8

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€29.44
Price
€17.05
GF Value